echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet Neurol: Comparison of apixaban and non-anticoagulation after anticoagulation-related cerebral hemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF)

    Lancet Neurol: Comparison of apixaban and non-anticoagulation after anticoagulation-related cerebral hemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF)

    • Last Update: 2021-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com







    • Between January 15, 2015 and July 6, 2020, a total of 101 post-cerebral hemorrhage patients were recruited (median age 78 years [IQR 73-83]; 55[54%] males and 46[46%] Female; 100 [99%] White and 1 [1%] Black), with a median age of 46 days (IQR 21-74)



      Literature source: Schreuder FHBM, van Nieuwenhuizen KM, Hofmeijer J, et al.
      Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial .
      Lancet Neurol.
      2021;20(11):907-916.
      doi:10.
      1016/S1474-4422(21)00298-2 Schreuder FHBM, van Nieuwenhuizen KM, Hofmeijer J, et al.
      Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial.
      Lancet Neurol.
      2021;20(11):907-916.
      doi:10.
      1016/S1474-4422(21) 00298-2

      Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.